Literature DB >> 15077129

Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.

V Spoulou1, M Giannaki, M Vounatsou, C Bakoula, S Grafakos.   

Abstract

Measles, mumps and rubella (MMR) vaccine-induced long-term immunity was studied in 30 children with bone marrow transplants (BMT). Immunity at baseline for MMR was 13.3, 33.3 and 66.6%, respectively. MMR vaccination failed to induce adequate and persistent responses to measles and mumps; seropositivity at 1 and 12 months for measles was 26.6 and 23.3% and for mumps 46.6 and 36.6%, respectively. In contrast, 27 of 30 children with a BMT were immune to rubella 1 month after immunization and retained protective antibody levels at 12 months. The MMR-induced anamnestic responses to rubella among all responders were associated with the production of high avidity antibodies. We conclude that a single dose of MMR given at 2 years after BMT induces suboptimal and short-lived immune responses to measles and mumps; a second dose should be recommended for paediatric BMT recipients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077129     DOI: 10.1038/sj.bmt.1704476

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation.

Authors:  Hiroto Inaba; Christine M Hartford; Deqing Pei; Meredith J Posner; Jie Yang; Randall T Hayden; Ashok Srinivasan; Brandon M Triplett; Jon A McCulllers; Ching-Hon Pui; Wing Leung
Journal:  Br J Haematol       Date:  2011-10-24       Impact factor: 6.998

2.  Persistence of Yellow Fever vaccine-induced antibodies after cord blood stem cell transplant.

Authors:  Vivian Iida Avelino-Silva; Marcos da Silva Freire; Vanderson Rocha; Celso Arrais Rodrigues; Yana Sarkis Novis; Ester C Sabino; Esper Georges Kallas
Journal:  Hum Vaccin Immunother       Date:  2015-11-30       Impact factor: 3.452

3.  Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

Authors:  Takekazu Iuchi; Seagal Teitz-Tennenbaum; Jianhua Huang; Bruce G Redman; Steven D Hughes; Mu Li; Guihua Jiang; Alfred E Chang; Qiao Li
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

4.  The Detailed Kinetics of Cytomegalovirus-specific T cell Responses after Hematopoietic Stem Cell Transplantation: 1 Year Follow-up Data.

Authors:  Seongman Bae; Jiwon Jung; Sun-Mi Kim; Young-Ah Kang; Young-Shin Lee; Yong Pil Chong; Heungsup Sung; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee; Sung-Han Kim
Journal:  Immune Netw       Date:  2018-01-22       Impact factor: 6.303

Review 5.  Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Authors:  C T Rieger; B Liss; S Mellinghoff; D Buchheidt; O A Cornely; G Egerer; W J Heinz; M Hentrich; G Maschmeyer; K Mayer; M Sandherr; G Silling; A Ullmann; M J G T Vehreschild; M von Lilienfeld-Toal; H H Wolf; N Lehners
Journal:  Ann Oncol       Date:  2018-06-01       Impact factor: 32.976

6.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.